65,437 trials
Generalized Myasthenia Gravis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in…
Covid19 · SARS-CoV Infection
Primary: Clinical Progression to Severe Covid — 154; 179; 105; 96 Participants
Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma
Primary: Percentage of 1 Year Overall Survival (OS) — 63.6 percentage of participants
Unicompartmental Knee Arthroplasty
Primary: 10 Year Survivorship of Components — 110 Participants
Healthy Participant
Primary: Maximum Observed Concentration (Cmax) of PF-07321332 — 4678; 5546 ng/mL — p=0.05
Visual Acuity
Primary: Monocular logMAR Visual Acuity — 0.051; 0.032; 0.044; 0.036 logMAR
Obesity
Primary: Completion Rate for First Trimester Scans — 66 percent
Retention, Urinary
Primary: Residual Urine at 1st Flow-stop During Nurse Catheterization — 59.4; 13.1; 0.4 mL — p=0.074
Smoking Cessation · HIV · Craving
Primary: Change in Attentional Bias iTBS (Intermittent Theta Burst Stimulation) Smoking — 1007.05; 566.89 milliseconds
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Primary: Measurement of Ratio of LDH to the Upper Limit of Normal (ULN) — 5.6; 1.9 Ratio of LDH:ULN (250 U/L)
Type 1 Diabetes
Primary: Comparison of the Mean Absolute Relative Difference When Including Patterns in Hypoglycemia Prediction. — -0.5; -3.1; -2.8 percent difference of MARD
Healthy
Primary: Number of Participants With Drug-related Adverse Events — 0; 0; 0; 0 Participants
Diabetic Foot Ulcer
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 3 Participants
HIV/AIDS
Primary: PrEP Uptake at Week 1 — 63 Participants
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Cumulative Incidence of CMV at 100 Days — 25.1; 13.8 cases per 100 persons